Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Completed Phase 1 Interventional

Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin

NCT01723527
View directory record Official record
Conditions
Cocaine-Related Disorders, HIV, Heroin Dependence
Interventions
Methadone, Buprenorphine, Employment-based drug abstinence reinforcement
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 20, 2026, 11:28 PM EDT
Not yet recruiting Not applicable Interventional

Measurement-Based Care to Support Buprenorphine-Naloxone Treatment in Outpatient Addiction Clinics

NCT07839182
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bup-MBC
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment for Opioid Dependent Offenders

NCT01082679
View directory record Official record
Conditions
Opioid Dependence
Interventions
Methadone, buprenorphine (Suboxone)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR

NCT03559179
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Opioid Wizard
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2 Interventional

Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13

NCT00000231
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 20, 2026, 11:28 PM EDT
Recruiting Phase 2 Interventional

Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

NCT06981195
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Insomnia, Orexin Antagonist
Interventions
Placebo, Lemborexant 10 MG
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional Results available

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
Buprenorphine/naloxone, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 20, 2026, 11:28 PM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 20, 2026, 11:28 PM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 2 Interventional

Treatment Efficacy for Drug Abuse and AIDS Prevention - 1

NCT00000210
View directory record Official record
Conditions
Cocaine-Related Disorders, Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
26 Years to 41 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1996
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase

NCT01135524
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
89
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairfield, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 20, 2026, 11:28 PM EDT
Recruiting Not applicable Interventional

Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine

NCT07278518
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Patient Decision Aid for Opioid Use Disorder
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

NCT00000327
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086
View directory record Official record
Conditions
Drug Interaction, Analgesics, Opioid Use Disorder
Interventions
Lemborexant, Placebo, Buprenorphine-naloxone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 20, 2026, 11:28 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

COVID-19-Related Opioid Treatment Policy Evaluation

NCT05028998
View directory record Official record
Conditions
Opioid-use Disorder, Alcohol Use Disorder
Interventions
Not listed
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 11:28 PM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

NCT02665208
View directory record Official record
Conditions
Smoking Cessation
Interventions
Treatment As Usual (TAU), Nicotine Replacement Therapies, Text Message Intervention (TMI)
Other · Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 20, 2026, 11:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 20, 2026, 11:28 PM EDT
Withdrawn Phase 4 Interventional

Psychopharmacological Treatment of Emotional Distress

NCT06133114
View directory record Official record
Conditions
Suicide Crisis Syndrome, Psychological Distress
Interventions
Clonazepam, Olanzapine, Buprenorphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adversity, Brain and Opioid Use Study

NCT06355778
View directory record Official record
Conditions
Opioid Use Disorder, Healthy
Interventions
Magnetic Resonance Imaging (MRI), Computer Tasks
Other · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 20, 2026, 11:28 PM EDT
Terminated No phase listed Observational

An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term

NCT04577144
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Online survey only
Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 20, 2026, 11:28 PM EDT